T Del Rosal1, M L García-García2, C Calvo3, F Gozalo3, F Pozo4, I Casas4. 1. Pediatrics Department, Hospital Universitario La Paz, Madrid, Spain. 2. Pediatrics Department, Hospital Severo Ochoa, Madrid, Spain. Electronic address: marialuz.hso@gmail.com. 3. Pediatrics Department, Hospital Severo Ochoa, Madrid, Spain. 4. Influenza and Respiratory Viruses Laboratory, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Abstract
BACKGROUND: Human bocavirus (HBoV) was recently discovered and identified as an important cause of respiratory infection in young children. However, the relationship between HBoV-bronchiolitis and the development of recurrent wheezing has not yet been established. OBJECTIVE: We designed this study in order to describe the mid-term outcome, regarding the development of recurrent wheezing and asthma of HBoV-bronchiolitis patients and to compare it with RSV-bronchiolitis infants. METHODS: We studied 80 children (10 with HBoV and 70 with RSV infection), currently aged ≥4 years and previously hospitalised during the seasons 2004-2009 due to acute bronchiolitis. Epidemiological and clinical data were collected through structured clinical interviews at the follow-up visit. Spirometry and skin prick tests to common food and inhaled allergens were performed. RESULTS: All HBoV-patients developed recurrent wheezing and half of them had asthma at age 5-7 years. Almost 30% required hospital admission for recurrent wheezing. Asthma (odds ratio (OR)=1.28) and current asthma (OR=2.18) were significantly more frequent in children with HBoV-bronchiolitis than in RSV-bronchiolitis. FEV1 values were 99.2±4.8 in HBoV-group vs. 103±11 in RSV-group, p: 0.09. No differences were found with respect to allergic rhinitis, atopic dermatitis, food allergy, proportion of positive prick tests, and family history of atopy or asthma. CONCLUSIONS: Severe HBoV-bronchiolitis in infancy was strongly associated with asthma at 5-7 years.
BACKGROUND:Human bocavirus (HBoV) was recently discovered and identified as an important cause of respiratory infection in young children. However, the relationship between HBoV-bronchiolitis and the development of recurrent wheezing has not yet been established. OBJECTIVE: We designed this study in order to describe the mid-term outcome, regarding the development of recurrent wheezing and asthma of HBoV-bronchiolitispatients and to compare it with RSV-bronchiolitisinfants. METHODS: We studied 80 children (10 with HBoV and 70 with RSV infection), currently aged ≥4 years and previously hospitalised during the seasons 2004-2009 due to acute bronchiolitis. Epidemiological and clinical data were collected through structured clinical interviews at the follow-up visit. Spirometry and skin prick tests to common food and inhaled allergens were performed. RESULTS: All HBoV-patients developed recurrent wheezing and half of them had asthma at age 5-7 years. Almost 30% required hospital admission for recurrent wheezing. Asthma (odds ratio (OR)=1.28) and current asthma (OR=2.18) were significantly more frequent in children with HBoV-bronchiolitis than in RSV-bronchiolitis. FEV1 values were 99.2±4.8 in HBoV-group vs. 103±11 in RSV-group, p: 0.09. No differences were found with respect to allergic rhinitis, atopic dermatitis, food allergy, proportion of positive prick tests, and family history of atopy or asthma. CONCLUSIONS: Severe HBoV-bronchiolitis in infancy was strongly associated with asthma at 5-7 years.
Authors: Le Duc Huy Ta; Gaik Chin Yap; Carina Jing Xuan Tay; Alicia Shi Min Lim; Chiung-Hui Huang; Collins Wenhan Chu; Paola Florez De Sessions; Lynette P Shek; Anne Goh; Hugo P S Van Bever; Oon Hoe Teoh; Jian Yi Soh; Biju Thomas; Mahesh Babu Ramamurthy; Daniel Y T Goh; Christophe Lay; Shu-E Soh; Yiong Huak Chan; Seang-Mei Saw; Kenneth Kwek; Yap-Seng Chong; Keith M Godfrey; Martin Lloyd Hibberd; Bee Wah Lee Journal: J Allergy Clin Immunol Date: 2018-02-13 Impact factor: 10.793
Authors: Amanda J Driscoll; S Hasan Arshad; Louis Bont; Steven M Brunwasser; Thomas Cherian; Janet A Englund; Deshayne B Fell; Laura L Hammitt; Tina V Hartert; Bruce L Innis; Ruth A Karron; Gayle E Langley; E Kim Mulholland; Patrick K Munywoki; Harish Nair; Justin R Ortiz; David A Savitz; Nienke M Scheltema; Eric A F Simões; Peter G Smith; Fred Were; Heather J Zar; Daniel R Feikin Journal: Vaccine Date: 2020-01-20 Impact factor: 3.641